The Next Drugs:
An Atlantic Policy Update on Biosimilars

June 7, 2017
Washington, DC

Biosimilars – and the policy and regulatory debates surrounding these complex large-molecule drugs – continue to be a hot topic in Washington.  A patent case in front of the Supreme Court and laws making their way through Congress have the potential to change the market and industry.

The Atlantic convened key stakeholders to discuss the state of and future for biosimilars. What impact will ongoing regulatory and policy considerations have? What can stakeholders expect when it comes to patents and exclusivity? And what effect will the priorities of leadership in Congress and the Administration have on the industry across the next few years?



Watch full session videos

Presented by

Atlantic Live

Speakers

Agenda

  • Wednesday, June 07
  • 8:20 a.m.WelcomeEmily Akhtarzandi, Managing Director, AtlanticLIVE
    Chester “Chip” Davis, Jr., President and CEO, Association for Accessible Medicines
  • 8:30 a.m.The Role of CongressRepresentative Peter Welch (D-VT)
    With Steve Clemons, Washington Editor at Large, The Atlantic
  • 8:50 a.m.The Patent LandscapeBruce Artim, Senior Director, Federal Government Affairs, Eli Lilly and Company
    Courtenay Brinckerhoff, Partner, Foley & Lardner LLP
    Phil Nickson, Associate General Counsel, Intellectual Property, Momenta Pharmaceuticals
    With Olga Khazan, Staff Writer, The Atlantic
  • 9:20 a.m.Closing ThoughtsEmily Akhtarzandi, AtlanticLIVE

Underwriter

Also in This Series

Upcoming Events

  • Food

    Harvest: Transforming the Food We Eat

    In a conversation about the future of food, The Atlantic will convene the farmers and foodies, techies and tinkerers developing the culinary discoveries of tomorrow.

  • Health Care

    PULSE: The Atlantic Summit on Health Care

    Drawing from leading thinkers across the country, in combination with Boston's revered medical community, The Atlantic will uncover the stories of patients and families, experts and professionals to explore the state and future of health care.